CA2417874A1 - Use of ox-2 inhibitors for the treatment of cancer - Google Patents
Use of ox-2 inhibitors for the treatment of cancer Download PDFInfo
- Publication number
- CA2417874A1 CA2417874A1 CA002417874A CA2417874A CA2417874A1 CA 2417874 A1 CA2417874 A1 CA 2417874A1 CA 002417874 A CA002417874 A CA 002417874A CA 2417874 A CA2417874 A CA 2417874A CA 2417874 A1 CA2417874 A1 CA 2417874A1
- Authority
- CA
- Canada
- Prior art keywords
- agent
- protein
- molecule
- effective amount
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Methods and compositions for regulating tumor growth are disclosed. For reducing tumor growth, agents that inhibit OX-2 are administered. Such metho ds are useful in treating cancer. For enhancing tumor growth, an OX-2 protein o r a nucleic acid encoding an OX-2 protein is administered. Such methods are useful in studying cancer and/or tumor metastasis.
Claims (9)
1. A use of an effective amount of an agent that inhibits an OX-2 protein to prepare a medicament to prevent, inhibit or reduce tumor cell growth.
2. A use according to claim 1 wherein the agent is a molecule that binds the OX-2 protein.
3. A use according to claim 2 wherein the agent is an antibody.
4. A use according to claim 1 wherein the agent is an antisense oligonucleotide that is complimentary to a nucleic acid sequence from an OX-2 gene.
5. A pharmaceutical composition for use in preventing, inhibiting or reducing tumor cell growth comprising an effective amount of an agent that inhibits OX-2 in admixture with a suitable diluent or carrier.
6. A composition according to claim 5 wherein the agent is a molecule that binds the OX-2 protein.
7. A composition according to claim 6 wherein the molecule is an antibody.
8. A composition according to claim 5 wherein the agent is an antisense oligonucleotide that is complimentary to a nucleic acid sequence from an OX-2 gene.
9. A use of an effective amount of an OX-2 protein to prepare a medicament to induce tumor cell growth or metastasis.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22272500P | 2000-08-03 | 2000-08-03 | |
| US60/222,725 | 2000-08-03 | ||
| PCT/CA2001/001111 WO2002011762A2 (en) | 2000-08-03 | 2001-07-30 | Methods and compositions for modulating tumor growth |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2417874A1 true CA2417874A1 (en) | 2002-02-14 |
| CA2417874C CA2417874C (en) | 2012-10-02 |
Family
ID=22833418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2417874A Expired - Fee Related CA2417874C (en) | 2000-08-03 | 2001-07-30 | Use of ox-2 inhibitors for the treatment of cancer |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2001278338A1 (en) |
| CA (1) | CA2417874C (en) |
| WO (1) | WO2002011762A2 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE406385T1 (en) * | 2000-11-22 | 2008-09-15 | Trillium Therapeutics Inc | SHORTENED CD200 |
| AU2004217434B2 (en) * | 2000-12-08 | 2010-08-26 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US20040198661A1 (en) * | 2000-12-08 | 2004-10-07 | Bowdish Katherine S. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US20060057651A1 (en) | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| EP1341902A2 (en) | 2000-12-08 | 2003-09-10 | Alexion Pharmaceuticals, Inc. | Chronic lymphocytic leukemia cell line and its use for producing an antibody |
| US9249229B2 (en) | 2000-12-08 | 2016-02-02 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US7408041B2 (en) | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| WO2003077947A1 (en) * | 2002-03-15 | 2003-09-25 | Schering Corporation | Methods of modulating cd200 receptors |
| EP1585545A4 (en) * | 2002-12-27 | 2006-04-12 | Schering Corp | Methods of inducing and maintaining immune tolerance |
| AU2012211347B9 (en) * | 2004-07-20 | 2015-06-18 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| SG10201400426XA (en) | 2006-01-12 | 2014-07-30 | Alexion Pharma Inc | Antibodies to ox-2/cd200 and uses thereof |
| EP2185593B1 (en) | 2007-07-25 | 2017-12-13 | Alexion Pharmaceuticals, Inc. | Compositions for treating autoimmune disease |
| CA2786692A1 (en) | 2010-01-11 | 2011-07-14 | Alexion Pharmaceuticals, Inc. | Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies |
| EP2534178A4 (en) | 2010-02-11 | 2013-08-07 | Alexion Pharma Inc | Therapeutic methods using an ti-cd200 antibodies |
| WO2012178137A1 (en) | 2011-06-24 | 2012-12-27 | Gillies Stephen D | Light chain immunoglobulin fusion proteins and methods of use thereof |
| KR102531889B1 (en) | 2016-06-20 | 2023-05-17 | 키맵 리미티드 | Anti-PD-L1 and IL-2 cytokines |
| WO2019067499A1 (en) | 2017-09-27 | 2019-04-04 | Alexion Pharmaceuticals, Inc. | Biomarker signature for predicting tumor response to anti-cd200 therapy |
| US11802154B2 (en) | 2017-12-20 | 2023-10-31 | Alexion Pharmaceuticals, Inc. | Humanized anti-CD200 antibodies and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE319825T1 (en) * | 1997-11-07 | 2006-03-15 | Trillium Therapeutics Inc | METHODS AND COMPOSITIONS FOR IMMUNOMODULATION |
-
2001
- 2001-07-30 WO PCT/CA2001/001111 patent/WO2002011762A2/en active Application Filing
- 2001-07-30 CA CA2417874A patent/CA2417874C/en not_active Expired - Fee Related
- 2001-07-30 AU AU2001278338A patent/AU2001278338A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2417874C (en) | 2012-10-02 |
| WO2002011762A2 (en) | 2002-02-14 |
| WO2002011762A3 (en) | 2003-03-13 |
| AU2001278338A1 (en) | 2002-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2417874A1 (en) | Use of ox-2 inhibitors for the treatment of cancer | |
| ATE334657T1 (en) | INHIBITION OF BCL-2 PROTEIN EXPRESSION BY LIPOSOMAL ANTISENSE OLIGODEOXYNUCLEOTIDES | |
| GEP20053424B (en) | Pyrimidine-2,4,6-Trione Metalloproteinase Inhibitors | |
| WO2000063364A3 (en) | Methods and compositions for inhibiting the function of polynucleotide sequences | |
| EP1379251A4 (en) | Inhibitors of akt activity | |
| GB2370774A (en) | Anti-infective compositions for treating disordered tissue such as cold sores | |
| WO2004076644A3 (en) | A composition for delivering an agent to a target cell and uses thereof | |
| Feldman et al. | Binding of α2-macroglobulin to hepatocytes: mechanism of in vivo clearance | |
| AU7621600A (en) | Human rnase h and oligonucleotide compositions thereof | |
| WO2003070283A3 (en) | Agent for inhibiting development or progress of proliferative diseases and especially cancer diseases and pharmaceutical composition containing said agent | |
| MY127082A (en) | Synergistic methods and compositions for treating cancer | |
| GEP20043363B (en) | Indazole Compounds, Pharmaceutical Compositions, and Methods for Inhibiting Cell Proliferation | |
| WO2002009684A8 (en) | Erbb-2 selective small molecule kinase inhibitors | |
| IL162836A (en) | Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments and pharmaceutical compositions thereof | |
| NZ515964A (en) | A method for the prophylaxis and/or treatment of medical disorders | |
| EA200500300A1 (en) | CYTOTOXIC AGENTS CONTAINING NEW STRONGLY ACTIVE TAXANS, AND THEIR THERAPEUTIC APPLICATION | |
| HK1033574A1 (en) | Anitumor agents | |
| Dalbies et al. | Linkage isomerization reaction of intrastrand cross-links in trans-diamminedichloroplatinum (II)-modified single-stranded oligonucleotides | |
| WO2003017939A3 (en) | Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment | |
| AU2007263526B2 (en) | Cancer therapy using Bcl-XL-specific siNA | |
| UA81634C2 (en) | Pharmaceutical compoosition containing urease for inhibiting cancer cell growth | |
| AU3881095A (en) | Double-stranded oligonucleotide and carcinostatic agent containing the same as active ingredient | |
| IL164674A0 (en) | A dna enzyme to inhibit plasminogen activator inhibitor-1 | |
| HK1060136A1 (en) | Human cervical cance suppressor protein, polynucleotide encoding the protein, cell transformed with the polynucleotide and method for suppressing proliferation of cancer cell using the expression vector | |
| MXPA02010813A (en) | Bis (n,n bis (2 haloethyl)amino) phosphoramidates as antitumor agents. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20140730 |